[1]SHAIB Y, EL-SERAG HB.The epidemiology of cholangiocarcinoma[J].Semin Liver Dis, 2004, 24 (2) :115-125.
|
[2]BLECHACZ B, GORES GJ.Cholangiocarcinoma:Advances in pathogenesis, diagnosis, and treatment[J].Hepatology, 2008, 4 (1) :308-321.
|
[3]PADIA SA.Intrahepatic cholangiocarcinoma[J].Tech Vasc Interv Radiol, 2015, 18 (4) :227-235.
|
[4]SPOLVERATO G, KIM Y, ALEXANDRESCU S, et al.Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection[J].Ann Surg Oncol, 2016, 23 (1) :235-243.
|
[5]LENCIONI R, CROCETTI L.Image-guided ablation for hepatocellular carcinoma[J].Recent Results Cancer Res, 2013, 190:181-194.
|
[6]ZIEMLEWICZ TJ, WELLS SA, LUBNER MG, et al.Hepatic tumor ablation[J].Surg Clin North Am, 2016, 96 (2) :315-339.
|
[7]SIMO KA, HALPIN LE, MCBRIER NM, et al.Multimodality treatment of intrahepatic cholangiocarcinoma:A review[J].J Surg Oncol, 2016, 113 (1) :62-83.
|
[8]HAN K, KO HK, KIM KW, et al.Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma:Systematic review and meta-analysis[J].J Vasc Interv Radiol, 2015, 26 (7) :943-948.
|
[9]VALLE J, WASAN H, PALMER DH, et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med, 2010, 362 (14) :1273-1281.
|
[10]BRIDGEWATER J, GALLE PR, KHAN SA, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J].J Hepatol, 2014, 60 (6) :1268-1289.
|
[11]SØRENSEN JB, KLEE M, PALSHOF T, et al.Performance status assessment in cancer patients.An inter-observer variability study[J].Br J Cancer, 1993, 67 (4) :773-775.
|
[12]BRUIX J, SHERMAN M, LLOVET JM, et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver[J].J Hepatol, 2001, 35 (3) :421-430.
|
[13]EISENHAUER EA, THERASSE P, BOGAERTS J, et al.New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1) [J].Eur J Cancer, 2009, 45 (2) :228-247.
|
[14]GOLDBERG SN, CHARBONEAU JW, DODD GD, et al.Imageguided tumor ablation:Proposal for standardization of terms and reporting criteria[J].Radiology, 2003, 228 (2) :335-345.
|
[15]AMIN MA, GREENE FL, EDGE S, et al.AJCC Cancer Staging Manual[M].8th ed.New York:Springer, 2017.
|
[16]JARNAGIN WR, SHOUPM.Surgical management of cholangiocarcinoma[J].Semin Liver Dis, 2004, 24 (2) :189-199.
|
[17]BOEHM LM, JAYAKRISHNAN TT, MIURA JT, et al.Comparative effective-ness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J].J Surg Oncol, 2015, 111 (2) :213-220.
|
[18]BUTROS SR, SHENOY-BHANGLE A, MUELLER PR, et al.Radiofrequency ablation of intrahepatic cholangiocarcinoma:Feasability, local tumor control, and long-term outcome[J].Clin Imaging, 2014, 38 (4) :490-494.
|
[19]KIM JH, WON HJ, SHIN YM, et al.Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma[J].AJR Am J Roentgenol, 2011, 196 (2) :205-209.
|
[20]YANG GW, ZHAO Q, QIAN S, et al.Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma[J].Onco Targets Ther, 2015, 8:1245-1250.
|
[21]SEIDENSTICKER R, SEIDENSTICKER M, DOEGEN K, et al.Extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma[J].Gastroenterol Res Pract, 2016, 2016:8732521.
|
[22]CARRAFIELLO G, LAGANA D, COTTA E, et al.Radiofrequency ablation of intrahepatic cholangiocarcinoma:Preliminary experience[J].Cardiovasc Intervent Radiol, 2010, 33 (7) :835-839.
|